Peer-reviewed veterinary case report
Treatment of symptomatic dogs with Glucantime and Leish-110f vaccine
By Miret, Jorge et al.·Published in Vaccine·2008·Laborató, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis.
- Species:
- dog
Plain-English summary
A group of 30 dogs with symptoms of leishmaniasis, a serious infection caused by the Leishmania parasite, were treated with a combination of a standard medication called Glucantime and a new vaccine. The dogs were divided into groups to receive different treatments, including just the vaccine or a placebo. Those receiving the combination of Glucantime and the vaccine showed better overall health, fewer deaths, and a higher chance of survival compared to those who only received the standard treatment or placebo. This study suggests that adding the vaccine could enhance the effectiveness of existing treatments for canine leishmaniasis.
People also search for: dog leishmaniasis treatment · Glucantime for dogs · canine leishmaniasis vaccine
Abstract
The evaluation of the efficacy of an immunochemotherapy protocol to treat symptomatic dogs naturally infected with Leishmania chagasi was studied. This clinical trial had the purpose to test the combination of N-methyl meglumine antimoniate (Glucantime and the second generation recombinant vaccine Leish-110f plus the adjuvant MPL-SE to treat the canine leishmaniasis (CanL). Thirty symptomatic naturally infected mongrel dogs were divided into five groups. Animals received standard treatment with Glucantime or treatment with Glucantime Leish-110f + MPL-SEas immunochemotherapy protocol. Additional groups received Leish-110f + MPL-SE only, MPL-SE only, or placebo. Evaluation of haematological, biochemical (renal and hepatic function) and plasmatic proteins, immunological (humoral and cellular immune response) and the parasitological test revealed improvement of the clinical parameters and parasitological cure in dogs in both chemotherapy alone and immunochemotherapy cohorts. However, the immunotherapy and immunochemotherapy cohorts had reduced number of deaths, higher survival probability, and specific cellular reactivity to leishmanial antigens, in comparison with chemotherapy cohort only and control groups (adjuvant alone and placebo). These results support the notion of using well-characterized recombinant vaccine as an adjunct to improve the current chemotherapy of CanL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18328956/